Tetra Bio-Pharma Inc. today announced that it has temporarily suspended its phase 3 clinical program due to impurities found in its PPP001 investigational drug being administered to patients.
Crescita Therapeutics Inc. and Tetra Natural Health today announced an agreement to develop an enhanced version of Tetra’s dermatology portfolio using Crescita’s patented transdermal delivery technologies: Multiplexed Molecular Penetration Enhancer ("MMPE™") and DuraPeel™.
Tetra Bio-Pharma Inc. today announced it has entered into a definitive agreement with the shareholders (the "Vendors") of Panag Pharma Inc. for the previously-announced acquisition by Tetra of all of the issued and outstanding shares in the capital of Panag.
Tetra Bio-Pharma Inc. has announced that it filed a patent application for its PPP001 drug product. Tetra’s research has led to a significant discovery that has enabled the company to apply for patent protection.